These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8077983)

  • 41. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutant prevention concentrations of tetracycline, rifampicin and ciprofloxacin for Brucellae melitensis.
    Coban AY; Tanyel E; Tasdelen Fisgin N; Darka O; Tulek N; Durupinar B
    J Chemother; 2007 Oct; 19(5):596-8. PubMed ID: 18073161
    [No Abstract]   [Full Text] [Related]  

  • 43. Antimicrobial susceptibility testing of Brucella melitensis isolated from patients with acute brucellosis in a centre of Iran.
    Razzaghi R; Rastegar R; Momen-Heravi M; Erami M; Nazeri M
    Indian J Med Microbiol; 2016; 34(3):342-5. PubMed ID: 27514957
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria.
    MacGowan AP; Bowker KE; Holt HA; Wootton M; Reeves DS
    J Antimicrob Chemother; 1997 Oct; 40(4):503-9. PubMed ID: 9372419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro susceptibility of mycoplasmas to a new quinolone, BAY Y 3118.
    Renaudin H; Bébéar C
    Drugs; 1995; 49 Suppl 2():243-5. PubMed ID: 8549318
    [No Abstract]   [Full Text] [Related]  

  • 46. Antimicrobial susceptibilities of Brucella isolates from various clinical specimens.
    Bayram Y; Korkoca H; Aypak C; Parlak M; Cikman A; Kilic S; Berktas M
    Int J Med Sci; 2011 Mar; 8(3):198-202. PubMed ID: 21448305
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.
    Jones RN; Barrett MS; Erwin ME; Briggs BM; Johnson DM
    Diagn Microbiol Infect Dis; 1991; 14(4):319-30. PubMed ID: 1909615
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.
    Gootz TD; Brighty KE; Anderson MR; Schmieder BJ; Haskell SL; Sutcliffe JA; Castaldi MJ; McGuirk PR
    Diagn Microbiol Infect Dis; 1994 Aug; 19(4):235-43. PubMed ID: 7851087
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
    Wise R; Brenwald NP; Andrews JM; Boswell F
    J Antimicrob Chemother; 1997 Apr; 39(4):447-52. PubMed ID: 9145816
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
    Rotstein C; Amsterdam D; Beam TR; Mandell LA; Gorzynski EA
    Diagn Microbiol Infect Dis; 1993 Jul; 17(1):85-91. PubMed ID: 8395375
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolates.
    Barrett MS; Jones RN
    Diagn Microbiol Infect Dis; 1996 Feb; 24(2):113-6. PubMed ID: 9147907
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence of
    Beig M; Moradkasani S; Goodarzi F; Sholeh M
    Vector Borne Zoonotic Dis; 2024 Jan; 24(1):1-9. PubMed ID: 37862228
    [No Abstract]   [Full Text] [Related]  

  • 54. Comparative activity of the new fluoroquinolone Bay y3118 against 177 penicillin susceptible and resistant pneumococci.
    Spangler SK; Jacobs MR; Appelbaum PC
    Eur J Clin Microbiol Infect Dis; 1993 Dec; 12(12):965-7. PubMed ID: 8187796
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of the bactericidal activity of sparfloxacin, ofloxacin, levofloxacin, and other fluoroquinolones compared with selected agents of proven efficacy against Listeria monocytogenes.
    Cherubin CE; Stratton CW
    Diagn Microbiol Infect Dis; 1994 Sep; 20(1):21-5. PubMed ID: 7867294
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone.
    Wise R; Andrews JM; Brenwald N
    J Antimicrob Chemother; 1993 Apr; 31(4):497-504. PubMed ID: 8390433
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The in-vitro activity of two new quinolones: rufloxacin and MF 961.
    Wise R; Andrews JM; Matthews R; Wolstenholme M
    J Antimicrob Chemother; 1992 Jun; 29(6):649-60. PubMed ID: 1324239
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative in vitro activity of BAY Y 3118 with other fluoroquinolones.
    Molinari G; Schito GC
    Drugs; 1995; 49 Suppl 2():222-5. PubMed ID: 8549310
    [No Abstract]   [Full Text] [Related]  

  • 59. In vitro activity of lomefloxacin, a difluorinated quinolone, compared with other antimicrobials.
    Qadri SM; Lee GC; Ellis ME
    Chemotherapy; 1991; 37(3):166-74. PubMed ID: 1889304
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.